VA-REGULA
7.3.2024 08:01:27 CET | Business Wire | Press release
Liveness detection, both for individuals and their IDs, has become a cornerstone for a secure customer onboarding process. It is especially crucial in remote scenarios where document submission and verification are done via the Internet. With 65% of organizations globally relying on digital document checks in their online identity verification workflows, robust anti-fraud measures cannot be overrated.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240306499292/en/
Regula Document Reader SDK verifies the authenticity of an ID by checking its optically variable features (Photo: Business Wire)
Responding to this growing need for additional fraud protection, Regula has released an update for its Regula Document Reader SDK, a comprehensive solution for the most reliable and secure identity document verification. Thanks to improved neural networks, detecting and analyzing an identity document has become twice as fast. The software is now able to check dynamic security features that were previously eligible for verification in on-site scenarios only. These checks include, but are not limited to:
- Optically Variable Ink (OVI), which changes color depending on the angle of observation and illumination;
- Lenticular images, such as Multiple Laser Image (MLI) and Dynaprint, which consist of several initial images that appear depending on the angle of observation;
- Holograms, which reflect and form an image in reflected light when changing the angle of observation and illumination.
The updated Regula Document Reader SDK can reliably validate the authenticity of an ID by verifying such optically variable features. The solution employs advanced algorithms to analyze the presence of these features and images in documents, as well as their exact location, their content, and their liveness—e.g., changing colors, images, etc.—based on a specific document template. All a user needs to do is show their ID in front of a smartphone camera, and the rest is technology. With advanced document liveness detection, Regula Document Reader SDK effectively prevents identity fraud and other types of fraud, such as printed photo attacks and screen replay attacks.
Apart from that, all the client-side data retrieved during liveness checks and verification sessions can be securely transferred in encrypted form to the backend client’s server. Captured document images, session video, RFID session data, document liveness session data, and other processing data can be used to re-process a verification session in a customer’s trusted environment. This “zero-trust-to-mobile” approach adds an important layer of trustworthiness to the verification process, as it ensures that no data is manipulated by fraudsters while being transferred from mobile devices.
“Today, a mere $15 is all it takes to get an AI-generated ID — a golden ticket to illicit banking and crypto operations, and to circumventing anti-money laundering protocols. Amid this digital wild west, the necessity for document liveness checks has never been more critical. They serve as an essential counter-fraud measure, preventing identity theft and document tampering. By ensuring that a real document is being presented during onboarding, you can significantly enhance the verification process to prove that it is genuine and not a counterfeit or digital replica. That’s why we never stop researching and improving the functionality of Regula Document Reader SDK,” says Ihar Kliashchou, Chief Technology Officer at Regula.
To learn more about the recent update of Regula Document Reader SDK, please visit the official webpage.
About Regula
With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed.
Regula was named a Representative Vendor in the Gartner® Market Guide for Identity Verification in 2023.
Learn more at regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306499292/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
Seoul Viosys Eyes the $60 Billion AI Data Center Optical Communication Market with Opto Semiconductors27.4.2026 15:00:00 CEST | Press release
Joint Development Talks with Global Optical Communications companiesExpanding Partnerships to Provide Total Transceiver Solution1,800 Patents Secured for High-Performance Optical Communications Seoul Viosys (KOSDAQ: 092190), a company specializing in opto-semiconductor devices, is accelerating its entry into the next-generation photonics market supported by its proprietary “No-wire” and “No-package” fundamental patents—essential technologies for micrometer (μm)-scale miniaturization of opto-semiconductors—as well as its competitiveness in VCSEL technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426926495/en/ Seoul Viosys Optoelectronic Semiconductor Structure Subject to a Permanent U.S. Injunction in February 2026, Covering Similar Products and Employees (Image: Seoul Viosys) As the rapid expansion of AI drives a paradigm shift in data centers from copper-based to optical-based architectures, the company is streng
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
